General Information of the Protein
Protein ID
PT01241
Protein Name
Prolyl endopeptidase FAP
Secondarily
Protein Name
170 kDa melanoma membrane-bound gelatinase
Dipeptidyl peptidase FAP
Fibroblast activation protein alpha
Gelatine degradation protease FAP
Integral membrane serine protease
Post-proline cleaving enzyme
Serine integral membrane protease
Surface-expressed protease
Gene Name
FAP
Sequence
MKTWVKIVFGVATSAVLALLVMCIVLRPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWISGQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNASNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYLKQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATKYALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYPRTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVPAMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVLSICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITSGKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGSYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFSLSD
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Protease
>
Serine protease
>
Serine protease SC clan
>
Serine protease S9B subfamily
Function
Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as alpha-2-antiplasmin SERPINF2 and SPRY2 (PubMed:14751930, PubMed:16223769, PubMed:16480718, PubMed:16410248, PubMed:17381073, PubMed:18095711, PubMed:21288888, PubMed:24371721). Degrade also gelatin, heat-denatured type I collagen, but not native collagen type I and IV, vitronectin, tenascin, laminin, fibronectin, fibrin or casein (PubMed:9065413, PubMed:2172980, PubMed:7923219, PubMed:10347120, PubMed:10455171, PubMed:12376466, PubMed:16223769, PubMed:16651416, PubMed:18095711). Also has dipeptidyl peptidase activity, exhibiting the ability to hydrolyze the prolyl bond two residues from the N-terminus of synthetic dipeptide substrates provided that the penultimate residue is proline, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro (PubMed:10347120, PubMed:10593948, PubMed:16175601, PubMed:16223769, PubMed:16651416, PubMed:16410248, PubMed:17381073, PubMed:21314817, PubMed:24371721, PubMed:24717288). Natural neuropeptide hormones for dipeptidyl peptidase are the neuropeptide Y (NPY), peptide YY (PYY), substance P (TAC1) and brain natriuretic peptide 32 (NPPB) (PubMed:21314817). The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Plays a role in tissue remodeling during development and wound healing. Participates in the cell invasiveness towards the ECM in malignant melanoma cancers. Enhances tumor growth progression by increasing angiogenesis, collagen fiber degradation and apoptosis and by reducing antitumor response of the immune system. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner.
    Show/Hide
Uniprot ID
Primary ID:
Q12884

Secondarily ID:
O00199
Q53TP5
Q86Z29
Q99998
Q9UID4
    Show/Hide
Ensembl ID
ENSG00000078098
HGNC ID
HGNC:3590
Subcellular Location
Cell surface
Cell membrane
Cell projection
Lamellipodium membrane
Cell projection
Invadopodium membrane
Cell projection
Ruffle membrane
Membrane
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000023 , BTI-Tn-5B1-4
Compound ID Compound Name Compound Formula
CP0067540
(R)-1-(2-(1-naphthamido)acetyl)pyrrolidin-2-ylboronic acid
   Show/Hide
C17H19BN2O4
 2
1
IC50 = 19 nM
   TI
   LI
   LO
   TS
2
Ki = 7.9 nM
   TI
   LI
   LO
   TS
CP0365775
(2S,4S)-1-({(2S,4S)-4-[2-(1,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)-4-fluoropyrrolidine-2-carbonitrile
   Show/Hide
C20H21FN4O3
 1
1
IC50 = 20 nM
   TI
   LI
   LO
   TS
CP0089998
(2S)-1-({(2S,4S)-4-[2-(1,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)-4,4-difluoropyrrolidine-2-carbonitrile
   Show/Hide
C20H20F2N4O3
 2
1
IC50 = 22 nM
   TI
   LI
   LO
   TS
2
Ki = 1.3 nM
   TI
   LI
   LO
   TS
CP0417860
(2R)-1-{(2S, 4S)-4-[2-(1,3-Dihydroisoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidine-2-carbonyl}pyrrolidine-2-boronic Acid
   Show/Hide
C19H24BN3O5
 1
1
IC50 = 31 nM
   TI
   LI
   LO
   TS
CP0377209
(S)-1-((S)-2-amino-5-(1-oxoisoindolin-2-yl)pentanoyl)pyrrolidine-2-carbonitrile
   Show/Hide
C18H22N4O2
 1
1
IC50 = 54 nM
   TI
   LI
   LO
   TS
CP0386927
(2S)-1-{(2S,4S)-4-[2-(5-Fluoro-1,3-dihydroisoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidine-2-carbonyl}pyrrolidine-2-carbonitrile
   Show/Hide
C20H21FN4O3
 1
1
IC50 = 59 nM
   TI
   LI
   LO
   TS
CP0417859
(2S,4S)-1-{(2S,4S)-4-[2-(5-Chloro-1,3-dihydroisoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidine-2-carbonyl}-4-fluoropyrrolidine-2-carbonitrile
   Show/Hide
C20H20ClFN4O3
 1
1
IC50 = 63 nM
   TI
   LI
   LO
   TS
CP0398656
(2S)-1-({(2S,4S)-4-[2-(5-Chloro-1,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C20H21ClN4O3
 1
1
IC50 = 66 nM
   TI
   LI
   LO
   TS
CP0416406
(2S)-1-({(2S,4S)-5-Oxo-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]pyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C16H22N4O3
 1
1
IC50 = 73 nM
   TI
   LI
   LO
   TS
CP0405593
(2S)-1-{(2S, 4S)-4-[2-(1,3-Dihydroisoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidine-2-carbonyl}pyrrolidine-2-carbonitrile
   Show/Hide
C20H22N4O3
 1
1
IC50 = 79 nM
   TI
   LI
   LO
   TS
CP0398665
(2S)-1-({(2S,4S)-4-[2-(1,3-Dihydro-2H-isoquinol-2-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C21H24N4O3
 1
1
IC50 = 88 nM
   TI
   LI
   LO
   TS
CP0477589
(2S)-1-({(2S,4S)-4-[2-(5-Trifluoromethyl-1,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C21H21F3N4O3
 1
1
IC50 = 110 nM
   TI
   LI
   LO
   TS
CP0172402
(R)-1-(2-(1-oxoisoindolin-2-yl)acetyl)pyrrolidin-2-ylboronic acid
   Show/Hide
C14H17BN2O4
 1
1
IC50 = 120 nM
   TI
   LI
   LO
   TS
CP0386928
(2S)-1-({(2S,4S)-4-[2-[4-(4-Chlorophenyl)-3,6-dihydropyridin-1(2H)-yl]-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C23H25ClN4O3
 1
1
IC50 = 200 nM
   TI
   LI
   LO
   TS
CP0377210
(S)-1-((2S,4R)-4-(2-(isoindolin-2-yl)-2-oxoethyl)-5-oxopyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C20H22N4O3
 1
1
IC50 = 210 nM
   TI
   LI
   LO
   TS
CP0473229
2S)-1-({(2S,4S)-4-[2-(6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C19H22N4O3S
 1
1
IC50 = 250 nM
   TI
   LI
   LO
   TS
CP0507612
(2S)-1-({(2S,4S)-4-[2-[4-(4-Fluorophenyl)piperazin-1-yl]-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C22H26FN5O3
 1
1
IC50 = 510 nM
   TI
   LI
   LO
   TS
CP0117955
(S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-1-naphthamide
   Show/Hide
C18H17N3O2
 1
1
IC50 = 610 nM
   TI
   LI
   LO
   TS
CP0416420
2S)-1-({(2S,4S)-5-oxo-4-[2-Oxo-[2-(trifluoromethyl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]ethyl]pyrrolidin-2-yl}carbonyl)-pyrrolidine-2-carbonitrile
   Show/Hide
C19H21F3N6O3
 1
1
IC50 = 650 nM
   TI
   LI
   LO
   TS
CP0377211
(2S)-1-[{(2S,4S)-5-Oxo-4-(2-oxo-2-(piperidin-1-yl)ethyl)pyrrolidine-2-yl}carbonyl]pyrrolidine-2-carbonitrile
   Show/Hide
C17H24N4O3
 1
1
IC50 = 730 nM
   TI
   LI
   LO
   TS
CP0377219
(2S)-1-({(2S,4S)-4-[2-[4-(Pyridine-4-yl)-piperazin-1-yl]-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C21H26N6O3
 1
1
IC50 = 3200 nM
   TI
   LI
   LO
   TS
CP0417856
(2S)-1-({(2S,4S)-5-Oxo-4-[2-oxo-2-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethyl]pyrrolidin-2-yl}carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C18H20F3N7O3
 1
1
IC50 = 15000 nM
   TI
   LI
   LO
   TS
CP0469898
2-[(3S,5S)-5-{[(2S)-2-Cyanopyrrolidin-1-yl]carbonyl}-2-oxopyrrolidin-3-yl]-N-phenylacetamide
   Show/Hide
C18H20N4O3
 1
1
IC50 > 20000 nM
   TI
   LI
   LO
   TS
CP0903652
(2S)-1-((2S)-4-(2-(isoindolin-2-yl)-2-oxoethyl)-5-oxopyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
   Show/Hide
C20H22N4O3
 1
1
IC50 > 20000 nM
   TI
   LI
   LO
   TS
CP0405590
(3S,5S)-3-[2-(1,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-2-one
   Show/Hide
C18H21N3O3S
 1
1
IC50 > 50000 nM
   TI
   LI
   LO
   TS
CP0007316
(1R)-3-oxo-3-[3-(trifluoroethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorobenzyl)propylamine
   Show/Hide
C16H15F6N5O
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0048107
(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
   Show/Hide
C17H25N3O2
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0077736
(2S)-1-[(2S)-2-amino-4-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-4-oxobutanoyl]pyrrolidine-2-carbonitrile
   Show/Hide
C26H29F2N5O2
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0138655
(2S,3R)-2-amino-1-(isoindolin-2-yl)-3-methylpentan-1-one
   Show/Hide
C14H20N2O
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0280292
2-(S)-Amino-4-(2-chloro-benzylamino)-1-piperidin-1-yl-butan-1-one
   Show/Hide
C16H24ClN3O
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0377217
(2S)-1-{(2S,4S)-4-[2-(1,3-Dihydroisoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidine-2-carbonyl}pyrrolidine-2-carboxylic Acid tert-Butylamide
   Show/Hide
C24H32N4O4
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0405591
(3S,5S)-3-[2-(1,3-Dihydroisoindol-2-yl)-2-oxoethyl]-5-(pyrrolidine-1-carbonyl)pyrrolidin-2-one
   Show/Hide
C19H23N3O3
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
CP0405592
(2S)-1-({(2S,4S)-4-[2-(1,3-Dihydroisoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidine-2-carbonyl}pyrrolidine-2-carboxylic Acid Amide
   Show/Hide
C20H24N4O4
 1
1
IC50 > 100000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0067540
(R)-1-(2-(1-naphthamido)acetyl)pyrrolidin-2-ylboronic acid
   Show/Hide
C17H19BN2O4
 1
1 IC50 = 2.3 nM
CP0086238
N-[2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]quinoline-4-carboxamide
   Show/Hide
C17H14F2N4O2
 1
1 IC50 = 3.3 nM
CP0067537
(R)-1-((S)-2-amino-3-methylbutanoyl)pyrrolidin-2-ylboronic acid
   Show/Hide
C9H19BN2O3
 6
1 IC50 = 12 nM
2 IC50 = 24 nM
3 IC50 = 66 nM
4 IC50 = 70 nM
5 Ki = 5 nM
6 Ki = 66 nM
CP0365775
(2S,4S)-1-({(2S,4S)-4-[2-(1,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-5-oxopyrrolidin-2-yl}carbonyl)-4-fluoropyrrolidine-2-carbonitrile
   Show/Hide
C20H21FN4O3
 1
1 IC50 = 20 nM
CP0172402
(R)-1-(2-(1-oxoisoindolin-2-yl)acetyl)pyrrolidin-2-ylboronic acid
   Show/Hide
C14H17BN2O4
 2
1 IC50 = 93 nM
2 Ki = 7.5 nM
CP0007316
(1R)-3-oxo-3-[3-(trifluoroethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorobenzyl)propylamine
   Show/Hide
C16H15F6N5O
 4
1 IC50 = 5830 nM
2 IC50 > 20000 nM
3 IC50 > 35000 nM
4 IC50 > 100000 nM
CP0048107
(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
   Show/Hide
C17H25N3O2
 4
1 IC50 = 52000 nM
2 IC50 = 73000 nM
3 IC50 > 20000 nM
4 IC50 > 100000 nM
CP0039344
(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2,2,2-trifluoroacetic acid
   Show/Hide
C18H25N3O2
 1
1 IC50 > 1000 nM
CP0053608
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile
   Show/Hide
C18H21N5O2
 1
1 IC50 > 100000 nM
Clinical Information about the Protein
Target 1 ( Prolyl endopeptidase FAP (FAP) )
Target Type Clinical trial Target
Disease 1 Target-related Disease  1
1 Constitutional neutropenia [ICD-11: 4B00.0]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 Talabostat Phase 3
Constitutional neutropenia